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ABSTRACT 27 
The detection of Copy Number Variations (CNVs) from NGS data is under-exploited as chip-based 28 
or targeted techniques are still commonly used. We assessed the performances of a workflow 29 
centered on CANOES, a bioinformatics tool based on read depth information. 30 
We applied our workflow to gene panel (GP) and Whole Exome Sequencing (WES) data, and 31 
compared CNV calls to Quantitative Multiplex PCR of Short Fluorescent fragments (QMSPF) or 32 
array Comparative Genomic Hybridization (aCGH) results. 33 
From GP data of 3,776 samples, we reached an overall Positive Predictive Value (PPV) of 87.8%.  34 
This dataset included a complete comprehensive QMPSF comparison of 4 genes (60 exons) on 35 
which we obtained 100% sensitivity and specificity. 36 
From WES data, we first compared 137 samples to aCGH and filtered comparable events (exonic 37 
CNVs encompassing enough aCGH probes) and obtained an 87.25% sensitivity. The overall PPV 38 
was 86.4% following the targeted confirmation of candidate CNVs from 1,056 additional WES. 39 
In addition, our CANOES-centered workflow on WES data allowed the detection of CNVs of any 40 
size that were missed by aCGH. Overall, switching to a NGS-only approach should be cost-41 
effective as it allows a reduction in overall costs together with likely stable diagnostic yields. Our 42 
bioinformatics pipeline is available at : https://gitlab.bioinfo-diag.fr/nc4gpm/canoes-centered-43 
workflow. 44 
 45 
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INTRODUCTION  50 
Copy-number variations (CNVs) are a major cause of Mendelian disorders (1) as well as risk 51 
factors for common diseases (2). With the advent of next-generation sequencing (NGS), a number 52 
of software tools have been developed to detect CNVs. Whole genome sequencing (WGS) is often 53 
presented as an almost universal technique allowing the assessment of almost any type of variation, 54 
including CNVs and other structural variations. WGS may eventually be used as a first-tier 55 
diagnostics tool in the context of genetically highly heterogeneous disorders. However, the 56 
detection of structural variations from data generated using the technology of short read sequencing 57 
is still associated with a number of false positives. Such events can be detected using a plethora of 58 
bioinformatics tools based on different principles, including Depth Of Coverage (DOC) 59 
information, relative position of paired reads, split reads and DeNovo Assembly (3). Besides the 60 
development of WGS, targeted sequencing of gene panels and whole exome sequencing (WES) 61 
remain of primary use in many diagnostics and research laboratories. They are indeed still 62 
considered as more affordable and of easier access as they can be processed using usual informatics 63 
facilities accessible to most laboratories. Moreover, the input of WGS is questioning in disorders 64 
with low genetic heterogeneity and high phenotypic specificity. Hence, gene panels and WES 65 
remain largely used .  66 
The detection of CNVs from exonic capture-based targeted sequencing solutions primarily relies on 67 
DOC information (4,5). Tools based on DOC information compare one sample to a reference, and 68 
predict deletions or duplications depending on the increase or decrease of the DOC as compared to 69 
the reference (figure 1).  As each tool was set up and trained on a specific dataset, one of the main 70 
challenges is to evaluate the specificity and sensitivity of a given software tool on large datasets. 71 
Studies evaluating the diagnostic performances of CNV detection pipelines are scarce although they 72 
appear to be critical for their use in routine procedures. 73 
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In order to optimize CNV detection from NGS data, a classical approach consists in running 74 
multiple tools in parallel and then aggregate the results to keep a CNV as candidate only if multiple 75 
tools called it (6). As it is more effective to do so with tools using different types of bioinformatics 76 
methods (DOC, split reads, etc.), this combinatory approach is most adapted when working on 77 
WGS, or at least if most of the intergenic or intronic regions – where breakends are more frequently 78 
found – are captured. Here, we decided to focus on one tool using the DOC approach as it still 79 
remains the most adapted one for exonic capture. In a precision workflow approach, we developed a 80 
workflow based on the already existing software tool CANOES (7). Briefly, CANOES adopts a 81 
pooling strategy to build its reference model, and uses a Hidden Markov Model to represent the 82 
DOC of this model. Lastly, it confronts the samples to the reference in order to call candidate 83 
deletions or duplications. 84 
We performed a diagnostic performance evaluation of this workflow regarding gene panel and WES 85 
data, in two steps. First, we compared CNV calls with a reference technique, namely a 86 
comprehensive assessment by Quantitative Multiplex PCR of Short Fluorescent fragments 87 
(QMPSF) (8) or array comparative genomic hybridization (aCGH), regarding targeted gene panel 88 
and WES data, respectively. Second, we implemented our workflow in our routine procedures and 89 
performed an additional evaluation of the positive predictive value of our CANOES-centered 90 
workflow using targeted confirmation of CNVs using an independent targeted technique. 91 
 92 
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 93 
MATERIAL AND METHODS 94 
Gene panel sequencing 95 
In order to evaluate our workflow, we analyzed data from three gene panels (for detailed 96 
information, see supplementary table 1). Patients provided informed written consent for genetic 97 
analyses in a diagnostics setting. 98 
Panel 1 was set up to focus on genes involved in predisposition to colorectal cancer and digestive 99 
polyposis or Li-Fraumeni syndrome (9). This panel was implemented in two successive versions. 100 
V1 was used to sequence 11 genes in 2,771 samples. V2 was used to sequence 15 genes (same 11 101 
genes plus 4) in 549 samples. In both versions and for all genes, exons and introns outside repeated 102 
sequences were captured. 103 
Panel 2 also has two successive versions and was designed to focus on two clinical indications: (i) 104 
hydrocephaly (3 genes) and (ii) Cornelia de Lange syndrome and differential diagnoses (24 genes in 105 
v1, 30 in v2). In total, 320 samples were sequenced using this panel (240 with v1, 80 with v2). For 106 
this panel, introns outside repeated sequences were captured only for two genes, namely L1CAM 107 
and NIPBL. 108 
Panel 3 was designed to focus on genes involved in non-specific Intellectual Disability. It has been 109 
used to analyses 220 samples and is composed of 48 genes (coding regions only). The list of genes 110 
is available upon request. 111 
 112 
Assessment of CNV calls from gene panel data: step 1 113 
For the comparison to a reference technique, we used data obtained from samples for which both 114 
NGS (panel 1, v1) and comprehensive QMPSF screening data were available (n=465). This 115 
QMSPF assessment included all 60 exons of 4 genes from this panel (APC, MSH2, MSH6, MLH1) 116 
and was applied to all 465 samples.  117 
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Assessment of CNV calls from gene panel data: step 2 119 
Following step 1, we implemented our CANOES-centered workflow in our routine diagnostics 120 
procedures on NGS data from all three panels (n=3,311 additional samples in total). We performed 121 
confirmations of candidate CNVs using QMPSF or Multiplex Ligation-dependent Probe 122 
Amplification (MLPA) only in samples with a CANOES call. Primers used for QMPSF screening 123 
and validation are available upon request. 124 
  125 
Whole-exome sequencing  126 
Patients provided informed written consent for genetic analyses either in a diagnostics or in a 127 
research setting, following the approval by our ethics committee.   128 
Whole exomes were sequenced in the context of diverse research and diagnostics purposes 129 
(supplementary table 1). Exomes were captured using Agilent SureSelect Human All Exon kits (V1, 130 
V2 V4+UTR, V5, V5+UTR and V6) (Agilent technologies, Santa Clara, CA, USA). Final libraries 131 
were sequenced on an Illumina Genome Analyser GAIIX (corresponding to exomes captured with 132 
the V1, V2 or V4UTR kit, n=10), or on an Illumina HiSeq2000, 2500 or 4000 with paired ends, 76 133 
or 100bp reads (Illumina, San Diego, Ca, USA). Exome sequencing was performed in 3 sequencing 134 
centers: Integragen (Evry, France) (n=6), the French National Center of Human Genomics Research 135 
(CNRGH, Evry, France) (n=1,065) and the Genome Quebec Innovation Center (Montreal, Canada) 136 
(n=128) (10). Exomes were all processed through the same bioinformatics pipeline following the 137 
Broad Institute Best Practices recommendations (11). Reads were mapped to the 1000 Genomes 138 
GRCh37 build using BWA 0.7.5a.(12). Picard Tools 1.101 (http://broadinstitute.github.io/picard/) 139 
was used to flag duplicate reads. We applied GATK (13) for short insertion and deletions (indel) 140 
realignment and base quality score recalibration. All quality checks were processed as previously 141 
described (10). 142 
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 143 
Assessment of CNV calls from whole exome sequencing data: step 1 144 
For the  comparison to a reference technique, we analyzed data from 147 unrelated individuals with 145 
both WES and aCGH data available.  146 
Array CGH Analysis. Oligonucleotide aCGH was performed as previously described (14). Briefly, 147 
high-resolution aCGH analysis was performed using the 1x1M Human High-Resolution Discovery 148 
Microarray Kit or the 4x180K SurePrint G3 Human CGH Microarray kit (Agilent Technologies, 149 
Santa Clara, California, USA), using standard recommended protocols. An in-house and sex-150 
matched genomic DNA pool of at least 10 control individuals was used as reference sample. 151 
Hybridization results were analyzed with the Agilent’s DNA-Analytics software (version 4.0.81, 152 
Agilent Technologies) or the Agilent Genomic Workbench (version 7.0, Agilent Technologies). Data 153 
were processed using the ADM-2 algorithm, with threshold set at 6.0 SD or 5.0 SD. CNVs of at 154 
least five or three consecutive probes were retained for analysis, respectively for the 1M and the 155 
180K arrays. 156 
WES/aCGH comparison. Array CGH enables the detection of genome-wide rearrangements thanks 157 
to the measurement of the deviation of the fluorescent signal of the patient as compared to a control 158 
DNA. The number of probes depends of the type of chip that is used (here, Agilent 1M or 180K). 159 
The threshold to consider a deletion or a duplication was set to the deviation of 5 or 3 consecutive 160 
probes respectively. This restricts the detection to CNVs of  8kb or  for 20kb Agilent 1M and 161 
Agilent180K chips, respectively, on average. On the contrary, as CANOES analysis is based on 162 
WES data, it is strictly restricted to CNVs covering exonic sequences, but it can detect CNVs as 163 
small as one single exon.  164 
In order to combine these approaches to evaluate the sensitivity of our workflow, we filtered out 165 
CNVs located in intronic and intergenic regions exclusively from the aCGH data (and on X and Y 166 
chromosomes for the samples processed without gonosome CNV calling). Moreover, as CANOES 167 
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analysis is based on the calculation of a mean and variance of coverage on a given genomic region, 168 
the detection of polymorphic rearrangements is very uncertain. For that reason, we also filtered out 169 
all polymorphic CNVs from aCGH data. We defined as polymorphic a CNV that overlaps at least at 170 
70% with CNVs reported in the Gold Standard section of the Database of Genomic Variants with a 171 
frequency superior to 1% (15).  172 
Regarding the evaluation of the positive predictive value of our workflow, we restricted our analysis 173 
to candidate non-polymorphic CNVs detected from WES data (i) that are theoretically detectable by 174 
aCGH as they encompass at least 3 or 5 probes, depending on the chip used and (ii) that do not 175 
overlap with segmental duplication regions among >50% of the CANOES target regions. 176 
As most aCGH data were processed using the hg18 genome as reference, we used the liftover tool 177 
from UCSC (https://genome.ucsc.edu/cgi-bin/hgLiftOver) to establish the correspondence to hg19. 178 
If there were no lift over possibility, we manually checked genes encompassing CNVs. 179 
 180 
Assessment of CNV calls from whole exome sequencing data: step 2 181 
Following step 1, we implemented our workflow in our routine procedures. Form additional 1056 182 
WES (supplementary table 1), we performed targeted confirmations following the detection of 183 
candidate CNVs by CANOES using QMPSF or ddPCR (16). We focused our confirmations on a list 184 
of 350 genes that belong to the so-called Aβ network (17), as all the samples used at this step were 185 
sequenced in the context of Alzheimer disease research. This list of genes was built thanks to 186 
literature curation on Alzheimer pathophysiology, independently of any genomic information. 187 
Candidate CNVs were selected for targeted confirmation if (i) they encompassed genes belonging 188 
to this network, and (ii) they were not polymorphic i.e. with a frequency below 1% in our dataset. 189 
Primers used for QMPSF or ddPCR validation are available upon request. 190 
 191 
CNV calling from NGS data using CANOES 192 
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The CANOES software tool implements an algorithm dedicated to the detection of quantitative 193 
genomic variations based on DOC information. Basically, CANOES requires DOC data for each 194 
target of the capture kit used for each of the sample that are analyzed together. It also integrates the 195 
GC content information of each target to reduce the background variability observed in high-196 
throughput sequencing data (18). The read depth was calculated using Bedtools (19), and the GC 197 
content was determined using the GATK suite.  198 
CANOES builds its statistical reference model from a subset of the samples included in the same 199 
analysis (at least 30 samples are recommended). To obtain the best possible fit, CANOES selects 200 
the samples that are the most correlated to the currently analyzed sample. This allows the detection 201 
of small CNVs, but also reduces the detection susceptibility of recurrent events. CANOES uses a 202 
Hidden Markov Model to represent the variability of the DOC distribution built from the selected 203 
samples. Then, it uses the Viterbi algorithm to assign deletions, duplications or normal regions. 204 
After the calling step, a 'Not Applicable' (NA) score is attributed to all CNVs from samples carrying 205 
more than 50 rearrangements. Such samples are usually characterized by higher or lower average 206 
read depth and cannot be compared to the reference model. All CNVs assigned with an NA score 207 
were thus removed from further analyses. As CANOES used the capture kit definition to detect 208 
CNVs, boundaries of events were defined by the start position of the first target and the end position 209 
of the last target detected as deviated in comparison with the model. 210 
 211 
A CANOES-centered workflow 212 
To optimize CANOES performances, we focused on two different approaches, a methodological 213 
approach in sample selection and a bioinformatics approach (Figure 2). 214 
As previously described, CANOES defines a statistical model for a particular sample from a 215 
judicious selection of other samples included in the analysis. The first step of our workflow 216 
consisted in the implementation of rules to select the samples that should better be analyzed 217 
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together. In order to get enough material to build an efficient statistical model and following the 218 
CANOES recommendations, we always worked with at least 30 samples. Importantly, we analyzed 219 
samples with the less technical variability from each other. Practically, this consists in analyzing 220 
samples from the same run, and not to merge multiple runs if not necessary. When merging multiple 221 
runs was inevitable (e.g., sequencing of less than 30 samples per run), we combined sequencing 222 
runs from the same platform and processed using the same technical conditions, including the same 223 
number of samples per lane in order to reduce read depth variability from each sample. Of note, 224 
CANOES is not originally set up for the analysis of CNVs on gonosomes, but we implemented 225 
modifications in the original script in order to include gonosomes in our analyses. Hence, we ran 226 
our workflow after gathering either n≥30 males or N≥30 females for the analysis of gene panels 2 227 
and 3 that contain X-linked genes and of WES data. 228 
 229 
Bioinformatics optimization 230 
The first step consisted in the modification of the target definition from the capture kit information. 231 
We decided to merge close targets (less than 30 pb) if they covered the same exon. Concerning gene 232 
panels that include introns, we decided to split large targets that include both intronic and exonic 233 
regions. 234 
In order to gain flexibility in our analysis and to be able to add or remove samples easily, we 235 
implemented a two-step strategy consisting in (i) performing the read count step for each sample 236 
separately, and then (ii) aggregating selected samples before running CANOES. Doing so allowed, 237 
for example, intra-familial analyses including patient-parent trio approaches, where cases can be 238 
analyzed without taking related samples into account, preventing biasing the statistical model. 239 
Finally, we removed non-informative regions from our analyses. We considered a region as non-240 
informative if more than 90% of the samples each had less than 10 reads on the target. Then, we 241 
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called the CNVs using CANOES, and annotated the results using AnnotSV (20) in order to get 242 
additional information about the possible effect and populations frequencies. 243 
 244 
Nextflow integration 245 
In order to complete our optimization of processing and analysis time, we integrated our 246 
bioinformatics pipeline into Nextflow, a data-driven workflow manager (21). This software tool 247 
allows a quick deployment of new pipelines on different kind of computational environments, from 248 
local computers to a cloud environment. Another interest of Nextflow is to increase the performance 249 
by distributing the different steps of the workflow in regards to the computational resources 250 
available. The complete workflow, including the specific adaption of CANOES to analyze 251 
gonosomes, is available on https://gitlab.bioinfo-diag.fr/nc4gpm/canoes-centered-workflow. 252 
 253 
RESULTS 254 
After building a workflow centered on the CANOES tool, we assessed its performances in the 255 
context of (i) gene panel NGS data and (ii) WES data, both generated following capture and 256 
Illumina short read sequencing. 257 
 258 
Gene panel sequencing data 259 
We first evaluated the performances of the CANOES tool using targeted sequencing data of a panel 260 
of 11 genes (panel 1, n=465 samples). In parallel, all samples were assessed using custom 261 
comprehensive QMPSF assessing the presence or absence of a CNV encompassing any of the 60 262 
coding exons of 4 of these genes. We identified 14 CNVs by QMPSF (12 deletions, 2 duplications, 263 
size range: [1,556pb – 97Kpb]). All of them were accurately detected by our CANOES-based 264 
workflow from NGS data (Table 1). In addition, no additional CNV was called by CANOES, 265 
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allowing us to obtain a sensitivity and a specificity of 100% (95%CI:[73.24-100]) for those 4 genes. 266 
(see supplementary table 2). 267 
To further assess the Positive Predictive Value (PPV) of our workflow in the identification of CNVs 268 
from gene panels, we applied it to additional NGS data obtained from 3 gene panels (2,222 samples 269 
from panel 1, 320 samples from panel 2, and 220 samples from panel 3). We detected 101 candidate 270 
CNVs in 98 samples and assessed their presence using either QMPSF or MLPA (Table 2). We 271 
validated 87/101 CNVs (86.13%, 95%CI:[77.50-91.94], false positive rate: 13.9%). Overall, the 272 
PPV of our workflow applied to gene panel sequencing data was 87.83% (95%CI:[80.01-92.94]). 273 
True positive calls of our workflow were 73 deletions (size range: [391pb – 1.06Mpb]) and 16 274 
duplications (size range: [360pb – 39.4Kpb]) (see supplementary table 3). False positives were 275 
mainly deletions (10/14) and 5 of them were monoexonic. 276 
 277 
Whole exome sequencing data 278 
We then evaluated the performances of our workflow for the detection of CNVs from WES data. 279 
We first applied our workflow to the data obtained from 147 samples with both WES (average 280 
depth of coverage = 110x) and aCGH data available (50 samples assessed with the Agilent 1M chip 281 
and 97 samples with the Agilent 180k chip). Overall, 10 samples were removed due to a high or low 282 
number of rearrangements detected by aCGH or exome, mostly due to low DNA quality or low 283 
coverage in WES. 284 
From aCGH data, we detected 1,873 CNVs over the 137 samples remaining, of which 102 were 285 
non-polymorphic exonic CNVs. Our workflow accurately detected 89 (87.2%) of them (Table 1, 286 
supplementary table 4). Among the CNVs that were missed by our workflow, 7 were large (from 14 287 
to 80kb) CNVs that encompassed only one (n=5) or two (n=2) targets defined by the capture kit 288 
(see figure 3). 289 
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In order to determine the PPV of our workflow from WES data, we selected 223 CNVs called by 290 
our workflow and (i) theoretically detectable by aCGH as encompassing at least 3 (180 k chips) or 5 291 
(1M chips) probes and (ii) which did not overlap with segmental duplication regions for more than 292 
50% of the CANOES targets. Of them, 190 (85.2%) CNVs were confirmed as true positives 293 
following aCGH data assessment (Table 1, supplementary table 5).  294 
Of note, an additional set of 519 candidate CNVs were detected by our CANOES-based workflow 295 
that overlapped less than 50% of segmental duplication regions but encompassed less than 3 (180 k 296 
chips) or 5 aCGH probes (1M chips). Hence, they were not reported by the CGH analysis tool and 297 
would then have been overlooked following classical aCGH data analysis. We did not perform 298 
targeted confirmation of all these candidate CNVs. Instead, with the aim to further assess the PPV 299 
of our workflow regarding exonic non-polymorphic CNVs of any size, we applied it to 1,056 300 
additional WES performed in the context of Alzheimer disease research (with no corresponding 301 
aCGH data). We selected non-polymorphic CNVs targeting 355 genes belonging to the Aβ network 302 
involved in the pathophysiology of Alzheimer disease (17), whatever their size. We validated 303 
108/122 candidate CNVs (88.5%, false positive rate: 11.5%) by QMPSF (22) or ddPCR (Table 2, 304 
supplementary table 6). True positive calls of our workflow were 39 deletions (size range: [165pb – 305 
24,2Mpb]) and 69 duplications (size range [166pb – 5,9Mpb]). Interestingly, among the 122 306 
candidate CNVs obtained from our workflow, 75 were considered to be theoretically detectable by 307 
aCGH 1M, and 47 were considered as not detectable by aCGH 1M. Among the ones theoretically 308 
detectable by aCGH, 71 were true positives (94.6%). Among the theoretically not detectable ones, 309 
37 were true positives (78.7%).  310 
Overall, the PPV of our CANOES-based workflow was 86.3% from WES data after taking into 311 
account results from step 1 and step 2 altogether. 312 
 313 
DISCUSSION 314 
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Multiple tools have been developed to detect CNVs from NGS data. As long as such tools are being 315 
implemented in diagnostic laboratories, there is a critical need to evaluate their performances. 316 
Previous studies showed a large diversity of performances, while a number was performed using 317 
simulated datasets (23). After having defined a CANOES-centered workflow, we applied it to three 318 
different gene panels and WES data. Overall, we reached very high detection performances 319 
following the comparison with independent techniques. 320 
From gene panel data, we obtained a 100% sensitivity among a set of 4 genes, the copy number of 321 
all coding exons of which having been assessed prior to NGS in 465 samples. In addition, we 322 
obtained a 90.3% PPV among all genes with a CANOES call. Such high performances have 323 
previously been reported for other tools applied to small NGS panels (24). Among 14 false 324 
positives, we observed recurrent events, which can be easily reported as so and be ignored in further 325 
analyses. We also observed false positive CNVs in regions homologous to pseudogenes. In that 326 
case, it is possible to reduce false positive calls by improving the design of the capture to reduce the 327 
chance that probes target the homologous regions, or by optimizing the alignment. 328 
Of note, for all genes of Panel 1 and two genes of Panel 2, introns were captured in addition to 329 
exons. This might have increased the chances to detect CNVs that can be considered as small from 330 
an exon-only point of view but that can actually be much larger at the genomic level. An advantage 331 
of capturing introns might indeed be a gain in statistical power for the normalization process: 332 
increasing the number of targets may increase the robustness of the model. Among 101 CNVs 333 
detected from NGS data from all 3 panels, 75 CNVs encompassed one of these genes with intronic-334 
plus-exonic capture. Interestingly, only 18 of these 75 CNVs encompassed a single coding exon. 335 
Such a frequency of monoexonic CNVs is not unexpected regarding mutation screens in MMR 336 
genes (monoexonic deletions accounting for 26.92 to 46.27% of all pathogenic deletions (25–27), or 337 
other rare diseases (28–31), for example. We hypothesize that all other CNVs, encompassing 338 
multiple targets, would probably have been easily detected, had the introns been excluded from the 339 
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capture design. Further analyses may be required to better assess the performances of our workflow 340 
from single exon CNVs and the effect of including introns or not in the capture design. The 341 
observed higher rate of false positives in CNV calls encompassing genes without introns captured 342 
(22.22%) may also require further assessments, 343 
We used here a precision workflow approach, focusing on the optimization of one tool based on 344 
DOC. Interestingly, as some of our genes included non-coding sequences in gene panels, these 345 
specific exonic-plus-intronic captures could provide us the possibility to apply complementary tools 346 
using different approaches, like the ones developed for WGS. This can indeed increase both 347 
detection performances of CNVs and the spectrum of structural variants that can be detectable in 348 
these data.  349 
Of note, all our panels included multiple genes. We do not expect that a design including a single 350 
gene, even with its intronic sequences, would reach the sufficient number of targets for CANOES to 351 
build a robust model.  352 
We also applied our workflow to multiple WES datasets and reached an overall PPV of 86.38 % 353 
(95%CI:[82.19 – 89.72]). As for gene panel CNV detection, a confirmation by an independent 354 
technique is hence still required following the detection of a candidate CNV from WES data, 355 
although this high value allows a limited number of molecular confirmations. One of the major 356 
features usually required to apply a new technique in a diagnostic workflow is a high sensitivity as 357 
compared to a reference technique. Here, we reached a sensitivity of 87.25% (95%CI:[78.84 – 358 
82.77]). Although the sensitivity was not 100%, it is important to notice that aCGH is considered as 359 
reference here although the spectrum of events that can be detected is still limited. When comparing 360 
our results to aCGH data, it appeared that we missed fewer events than the potential number of true 361 
positive CNVs that were missed by aCGH itself. Indeed, from aCGH data, we missed 13 CNVs, but 362 
our analyses called 519 candidate CNVs from corresponding WES data and which were 363 
theoretically undetectable by aCGH (i.e. either small CNVs or in regions with no aCGH probes 364 
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coverage). Our PPVs suggest that the vast majority are eventually true. There is no reason to think 365 
that some of the CNVs detected by CANOES only might not be as or more deleterious than CNVs 366 
detected by both techniques or exclusively by aCGH. Knowing that aCGH misses many CNVs, 367 
even using the high-sensitivity chips such as the Agilent 1M one, and even if other chip designs 368 
might increase aCGH performances on coding regions, switching to a WES-only approach for CNV 369 
detection in a diagnostic setting should not reduce the overall diagnostic yield while allowing a 370 
significant drop of costs. 371 
As compared to aCGH, CANOES allowed the identification of CNVs of any size in regions not 372 
covered by probes but also for small CNVs including few exons. In addition, it is important to 373 
notice that the majority of CANOES false negatives were also CNVs with only few exons, which 374 
implies few targets for CANOES although non-coding probes may help detect some of them by 375 
aCGH. This decreased rate of detection of CNVs encompassing few targets has already been shown 376 
in other datasets (32,33) and appears as a limitation inherent to DOC comparison methods. 377 
Of note, it is possible to increase the detection of small events or events in complex regions by 378 
using the “GenotypeCNV” function of CANOES. The aim of this function is to look precisely at 379 
specific regions and call the genotype of the sample for these specific regions, however it is 380 
associated with an increase in false positive calls (29), as well as an increase in time and 381 
computational resources needed.  In particular cases, when known core genes have already been 382 
identified in a given disorder, it is possible to combine our approach to call CNVs at the exome 383 
level and focus on specific genes using the GenotypeCNV function applied to every exon of these 384 
genes to increase the detection performances in core genes at the same time. 385 
Of note, beyond the above-mentioned limitations of CNV detection tools from NGS data, somatic 386 
CNVs remain a challenge, both for array-based technologies and for NGS-based tools (34). Among 387 
the CNVs detected by our workflow, at least one was considered as likely somatic, as suggested by 388 
QMPSF data. However, the sensitivity of DOC tools might remain low in this context (34). 389 
 17 
In conclusion, we performed an evaluation of the performances of a CNV detection workflow based 390 
on read depth comparison from capture-prepared NGS data, one of the most popular methods for 391 
NGS in research and diagnostic settings. We highlight very high sensitivity and positive predictive 392 
value, for both NGS gene panel and whole exome sequencing. Although the sensitivity was not 393 
perfect for WES data as compared to aCGH, a number of additional true calls were not detected by 394 
the so-called reference technique. This highlights the absence of a genuine gold standard up to now.  395 
Overall, we consider that switching to a NGS-only approach is cost-effective as it allows a 396 
reduction in overall costs together with likely stable diagnostic yields.  397 
 398 
ACKNOWLEDGEMENTS 399 
This study received fundings from Clinical Research Hospital Program from the French Ministry of 400 
Health (GMAJ, PHRC 2008/067), the JPND PERADES and France Génomique. This study was co-401 
supported by the Centre National de Référence Malades Alzheimer Jeunes (CNR-MAJ), European 402 
Union and Région Normandie. Europe gets involved in Normandie with the European Regional 403 
Development Fund (ERDF). 404 
 405 
CONFLICTS OF INTEREST 406 
None 407 
 408 
 18 
REFERENCES409 
1.  Itsara A, Wu H, Smith JD, Nickerson DA, Romieu I, London SJ, et al. De novo rates and 410 
selection of large copy number variation. Genome Res. 2010 Nov;20(11):1469–81.  411 
2.  Huguet G, Schramm C, Douard E, Jiang L, Labbe A, Tihy F, et al. Measuring and Estimating 412 
the Effect Sizes of Copy Number Variants on General Intelligence in Community-Based 413 
Samples. JAMA Psychiatry. 2018 01;75(5):447–57.  414 
3.  Hehir-Kwa JY, Pfundt R, Veltman JA. Exome sequencing and whole genome sequencing for 415 
the detection of copy number variation. Expert Rev Mol Diagn. 2015;15(8):1023–32.  416 
4.  Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, et al. Control-FREEC: 417 
a tool for assessing copy number and allelic content using next-generation sequencing data. 418 
Bioinforma Oxf Engl. 2012 Feb 1;28(3):423–5.  419 
5.  Krumm N, Sudmant PH, Ko A, O’Roak BJ, Malig M, Coe BP, et al. Copy number variation 420 
detection and genotyping from exome sequence data. Genome Res. 2012 Aug;22(8):1525–32.  421 
6.  Collins RL, Brand H, Karczewski KJ, Zhao X, Alföldi J, Khera AV, et al. An open resource of 422 
structural variation for medical and population genetics [Internet]. Genomics; 2019 Mar [cited 423 
2019 Oct 9]. Available from: http://biorxiv.org/lookup/doi/10.1101/578674 424 
7.  Backenroth D, Homsy J, Murillo LR, Glessner J, Lin E, Brueckner M, et al. CANOES: 425 
detecting rare copy number variants from whole exome sequencing data. Nucleic Acids Res. 426 
2014 Jul;42(12):e97.  427 
8.  Charbonnier F, Raux G, Wang Q, Drouot N, Cordier F, Limacher JM, et al. Detection of exon 428 
deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal 429 
cancer families using multiplex polymerase chain reaction of short fluorescent fragments. 430 
Cancer Res. 2000 Jun 1;60(11):2760–3.  431 
9.  Baert-Desurmont S, Coutant S, Charbonnier F, Macquere P, Lecoquierre F, Schwartz M, et al. 432 
Optimization of the diagnosis of inherited colorectal cancer using NGS and capture of exonic 433 
and intronic sequences of panel genes. Eur J Hum Genet EJHG. 2018;26(11):1597–602.  434 
10.  Le Guennec K, Nicolas G, Quenez O, Charbonnier C, Wallon D, Bellenguez C, et al. ABCA7 435 
rare variants and Alzheimer disease risk. Neurology. 2016 Jun 7;86(23):2134–7.  436 
11.  DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for 437 
variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 438 
2011 May;43(5):491–8.  439 
12.  Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. 440 
Bioinforma Oxf Engl. 2009 Jul 15;25(14):1754–60.  441 
13.  McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome 442 
Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing 443 
data. Genome Res. 2010 Sep 1;20(9):1297–303.  444 
 19 
14.  Rovelet-Lecrux A, Deramecourt V, Legallic S, Maurage C-A, Le Ber I, Brice A, et al. Deletion 445 
of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson 446 
disease. Neurobiol Dis. 2008 Jul;31(1):41–5.  447 
15.  MacDonald JR, Ziman R, Yuen RKC, Feuk L, Scherer SW. The Database of Genomic 448 
Variants: a curated collection of structural variation in the human genome. Nucleic Acids Res. 449 
2014 Jan;42(Database issue):D986-992.  450 
16.  Cassinari K, Quenez O, Joly-Hélas G, Beaussire L, Le Meur N, Castelain M, et al. A Simple, 451 
Universal, and Cost-Efficient Digital PCR Method for the Targeted Analysis of Copy Number 452 
Variations. Clin Chem. 2019 Sep;65(9):1153–60.  453 
17.  Campion D, Pottier C, Nicolas G, Le Guennec K, Rovelet-Lecrux A. Alzheimer disease: 454 
modeling an Aβ-centered biological network. Mol Psychiatry. 2016;21(7):861–71.  455 
18.  Benjamini Y, Speed TP. Summarizing and correcting the GC content bias in high-throughput 456 
sequencing. Nucleic Acids Res. 2012 May;40(10):e72.  457 
19.  Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. 458 
Bioinforma Oxf Engl. 2010 Mar 15;26(6):841–2.  459 
20.  Geoffroy V, Herenger Y, Kress A, Stoetzel C, Piton A, Dollfus H, et al. AnnotSV: an integrated 460 
tool for structural variations annotation. Berger B, editor. Bioinformatics [Internet]. 2018 Apr 461 
14 [cited 2018 Oct 2]; Available from: https://academic.oup.com/bioinformatics/advance-462 
article/doi/10.1093/bioinformatics/bty304/4970516 463 
21.  Di Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E, Notredame C. Nextflow enables 464 
reproducible computational workflows. Nat Biotechnol. 2017 Apr;35(4):316–9.  465 
22.  Le Guennec K, Quenez O, Nicolas G, Wallon D, Rousseau S, Richard A-C, et al. 17q21.31 466 
duplication causes prominent tau-related dementia with increased MAPT expression. Mol 467 
Psychiatry. 2017 Aug;22(8):1119–25.  468 
23.  Roca I, González-Castro L, Fernández H, Couce ML, Fernández-Marmiesse A. Free-access 469 
copy-number variant detection tools for targeted next-generation sequencing data. Mutat Res. 470 
2019 Mar;779:114–25.  471 
24.  Fowler A, Mahamdallie S, Ruark E, Seal S, Ramsay E, Clarke M, et al. Accurate clinical 472 
detection of exon copy number variants in a targeted NGS panel using DECoN. Wellcome 473 
Open Res. 2016 Nov 25;1:20.  474 
25.  Di Fiore F, Charbonnier F, Martin C, Frerot S, Olschwang S, Wang Q, et al. Screening for 475 
genomic rearrangements of the MMR genes must be included in the routine diagnosis of 476 
HNPCC. J Med Genet. 2004 Jan;41(1):18–20.  477 
26.  Taylor CF, Charlton RS, Burn J, Sheridan E, Taylor GR. Genomic deletions in MSH2 or 478 
MLH1 are a frequent cause of hereditary non-polyposis colorectal cancer: identification of 479 
novel and recurrent deletions by MLPA. Hum Mutat. 2003 Dec;22(6):428–33.  480 
27.  van der Klift H, Wijnen J, Wagner A, Verkuilen P, Tops C, Otway R, et al. Molecular 481 
characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, 482 
 20 
MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer 483 
(HNPCC). Genes Chromosomes Cancer. 2005 Oct;44(2):123–38.  484 
28.  Baker M, Strongosky AJ, Sanchez-Contreras MY, Yang S, Ferguson W, Calne DB, et al. 485 
SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. 486 
Neurogenetics. 2014 Mar;15(1):23–30.  487 
29.  David S, Ferreira J, Quenez O, Rovelet-Lecrux A, Richard A-C, Vérin M, et al. Identification 488 
of partial SLC20A2 deletions in primary brain calcification using whole-exome sequencing. 489 
Eur J Hum Genet EJHG. 2016;24(11):1630–4.  490 
30.  Guo X-X, Su H-Z, Zou X-H, Lai L-L, Lu Y-Q, Wang C, et al. Identification of SLC20A2 491 
deletions in patients with primary familial brain calcification. Clin Genet. 2019 Jul;96(1):53–492 
60.  493 
31.  Nicolas G, Rovelet-Lecrux A, Pottier C, Martinaud O, Wallon D, Vernier L, et al. PDGFB 494 
partial deletion: a new, rare mechanism causing brain calcification with leukoencephalopathy. 495 
J Mol Neurosci MN. 2014 Jun;53(2):171–5.  496 
32.  Miyatake S, Koshimizu E, Fujita A, Fukai R, Imagawa E, Ohba C, et al. Detecting copy-497 
number variations in whole-exome sequencing data using the eXome Hidden Markov Model: 498 
an ‘exome-first’ approach. J Hum Genet. 2015 Apr;60(4):175–82.  499 
33.  Samarakoon PS, Sorte HS, Kristiansen BE, Skodje T, Sheng Y, Tjønnfjord GE, et al. 500 
Identification of copy number variants from exome sequence data. BMC Genomics. 2014 Aug 501 
7;15:661.  502 
34.  Zare F, Dow M, Monteleone N, Hosny A, Nabavi S. An evaluation of copy number variation 503 
detection tools for cancer using whole exome sequencing data. BMC Bioinformatics. 2017 504 
May 31;18(1):286.  505 
 506 
 507 
 21 
 508 
FIGURE LEGENDS 509 
Figure 1. Principles of Depth Of Coverage (DOC) comparison. Schematic distribution of reads 510 
among three different samples over 5 sequenced exons. (A) absence of any CNV. (B) Duplication of 511 
two exons (2 and 3). (C) Deletion of exon 4. In order to call those CNVs, software tools have to 512 
establish a reference. Some tools compare paired data from the same patient, e.g. tumor tissue 513 
against germline, while others build their reference from a pool of samples and then compare a 514 
given sample to this reference, as the CANOES tool used in our workflow. 515 
 516 
Figure 2. CANOES-centered workflow.  File (square) with their format in parenthesis, and 517 
process (rounded) constituting the workflow. From the original capture kit definition, we merge 518 
closed target from the same exon, then do in parallel the DOC and the GC content estimation. We 519 
regroup DOC individual files depending on the project, sequencing batch, unrelated samples, and 520 
remove non-informative regions. The last steps consist in CNV calling using CANOES and 521 
annotation with annotSV. 522 
 523 
Figure 3. Example of a CNV detected by aCGH but missed by the CANOES-centered 524 
workflow.  525 
A CNV (highlight region) detected by a-CGH encompassing multiple CGH probes (1M probes 526 
array, in gray) but only one target from the SureSelect V5 capture kit. Of note, this deletion would 527 
have been missed by using a 180k probes array CGH (in black). 528 
 529 
Figure 4. Example of CNVs detected by the CANOES-centered workflow from WES data but 530 
missed by aCGH.  531 
A. The highlighted region represents the CNV called by the CANOES-centered workflow, 532 
encompassing one exon of RHCE. 533 
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B. View of the same region from DNA-Analytics (aCGH data 1M) in the same patient.This deletion 534 
was not called following aCGH data analysis as the number of deviated probes did not reach the 535 
threshold for calling. However, as 3 probes (in white) were deviated, this allows the confirmation of 536 
the deletion of the region.  537 
 538 
 539 
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